Table of Contents
Overview
New York, NY – Aug 04, 2025 : The Global Diabetic Retinopathy Market is expected to grow significantly over the coming decade. It is projected to reach a value of US$ 19.7 Billion by 2034, up from US$ 8.7 Billion in 2024. This reflects a strong CAGR of 8.5% from 2025 to 2034. North America leads the market with a 38.2% share and a valuation of US$ 3.3 Billion in 2024. The region benefits from advanced healthcare infrastructure, rising diabetes cases, and strong reimbursement frameworks supporting diabetic retinopathy (DR) diagnostics and treatment.
Diabetic retinopathy is a vision-threatening condition caused by prolonged high blood sugar. It damages retinal blood vessels and may lead to blurred vision or blindness. The disease progresses in stages, from mild nonproliferative retinopathy to the severe proliferative form. As it advances, abnormal blood vessels grow, leading to severe complications. The World Health Organization (WHO) predicts DR cases will rise from 146 million in 2014 to 180.6 million by 2030. Early detection is vital, as symptoms often appear in the later stages.
Long-term diabetes is a major risk factor for DR. The Wisconsin Epidemiologic Study of Diabetic Retinopathy reported that after 20 years of diabetes, 99% of type 1 and 60% of type 2 patients develop some form of DR. This shows how disease duration affects risk. Regular eye screenings are essential for early intervention. However, many patients remain unaware until their vision is affected. This underscores the need for widespread awareness and preventive care strategies across diabetic populations globally.
The global burden of diabetic retinopathy continues to rise. A meta-analysis revealed that around 103 million people had DR globally. This number is expected to grow to 161 million by 2045. In 2020 alone, DR led to 1.07 million cases of blindness and 3.28 million cases of visual impairment. In the U.S., 9.6 million people were affected in 2021. Of these, 1.84 million had vision-threatening DR. These figures highlight the urgent need for better management, diagnosis, and treatment of this condition.
Advancements in technology are driving improvements in DR screening. AI-powered tools are now being adopted to enhance detection accuracy. These systems offer sensitivity and specificity rates between 85.7% and 97.5%. AEYE Health’s AI-based system, AEYE-DS, received FDA approval in 2024. It allows for fast, reliable diagnosis and reduces the burden on specialists. The rise in diabetes due to aging and lifestyle changes is also fueling market demand. With a growing elderly population, the need for efficient diabetic eye care is more pressing than ever.

Key Takeaways
- Industry experts forecast the diabetic retinopathy market to hit US$ 19.7 billion by 2034, rising from US$ 8.7 billion in 2024.
- In 2024, Non-Proliferative Diabetic Retinopathy (NPDR) led the type category, accounting for more than 57.2% of the global market share.
- Anti-VEGF injections were the top treatment option in 2024, representing over 38.5% of the diabetic retinopathy treatment segment.
- Hospitals and clinics emerged as the leading end users in 2024, capturing around 46.1% of the global diabetic retinopathy market.
- North America held a dominant position in 2024, securing 38.2% market share, translating to a value of approximately US$ 3.3 billion.
Regional Analysis
In 2024, North America held a dominant position in the diabetic retinopathy market, capturing over a 38.2% share with a value of US$ 3.3 billion. This growth is driven by the rising number of diabetic patients across the United States and Canada. Diabetes remains a leading health concern in the region, increasing the risk of diabetic eye conditions. As a result, demand for early detection and treatment continues to rise. Access to advanced healthcare systems also supports regular eye screenings and timely treatment.
The region benefits from strong healthcare infrastructure and widespread use of therapies such as anti-VEGF injections and laser procedures. Public health programs actively promote awareness about diabetes-related eye problems, encouraging early intervention. Insurance coverage for diabetic eye care lowers treatment costs, making it more affordable for patients. Additionally, pharmaceutical companies in North America heavily invest in R&D. These innovations bring new treatment options to market, ensuring the region remains a major player in diabetic retinopathy care.
Segmentation Analysis
Type Segment Analysis
In 2024, Non-Proliferative Diabetic Retinopathy (NPDR) dominated the Type Segment with over 57.2% market share. This is mainly due to its higher occurrence in both Type 1 and Type 2 diabetes patients. NPDR often appears early in the disease, making it easier to detect during routine check-ups. Modern diagnostic tools like fundus photography and OCT help in early diagnosis. Standardized screening in primary care also supports this trend. Rising awareness and regular monitoring further increase the number of NPDR cases detected at early stages.
Treatment Segment Analysis
Anti-VEGF injections led the Treatment Segment in 2024 with a 38.5% share. They are preferred for their ability to reduce macular edema and improve vision. Their minimally invasive nature and fewer side effects make them the top choice for doctors. Corticosteroids are used when anti-VEGF fails, though side effects like cataracts limit their use. Laser therapy is now less popular due to newer injectable treatments. Surgeries like vitrectomy are reserved for severe cases but may grow slightly with improved surgical techniques and accessibility.
End User Segment Analysis
Hospitals and clinics captured over 46.1% market share in 2024 in the End User Segment. This is because they offer better access to skilled professionals and diagnostic tools. These facilities are often the first stop for patients needing diabetic retinopathy care. Ophthalmology centers followed closely, driven by demand for specialized eye care. They offer advanced technologies and faster services. The “Others” segment—like diagnostic labs and mobile units—has a smaller share but strong growth potential. These setups support early detection, especially in rural and semi-urban regions.
Key Players Analysis
The diabetic retinopathy market is moderately consolidated, with a few major players holding significant shares. Key companies are focusing on product innovation, partnerships, and expanding their global footprint. Novartis AG leads with drugs like Beovu® and Lucentis®, co-developed with Genentech. The company invests heavily in anti-VEGF therapies and emerging market access. Bayer AG maintains a strong presence with Eylea®, developed with Regeneron. It focuses on global distribution and life-cycle management of existing drugs, ensuring its steady growth in diabetic retinopathy care.
F. Hoffmann-La Roche Ltd plays a vital role in the market through Lucentis®. Its acquisition of Spark Therapeutics boosts its gene therapy capabilities. Roche’s strong pipeline includes biologics and sustained drug delivery systems. These advances are expected to reshape treatment methods. Other key players include Alimera Sciences, AbbVie Inc., ThromboGenics NV, and Quantel Medical. They focus on implants, laser systems, and novel therapies. Strategic acquisitions, geographic expansion, and higher R&D spending are common approaches used to grow their market positions.
Emerging Trends
Rising Adoption of AI-Based Screening Tools
AI is transforming how diabetic retinopathy is diagnosed. AI-powered tools can scan retinal images and detect early signs of damage. This helps doctors make faster and more accurate decisions. These tools are being used more in hospitals and remote clinics. They reduce the burden on specialists and speed up diagnosis. As the number of diabetic patients rises, the need for fast screening is growing. AI also helps in tracking disease progression over time. The technology is especially useful in areas with limited access to eye care experts. This trend is expected to grow rapidly in the coming years.
Shift Toward Non-Invasive Imaging Techniques
Patients and doctors are now preferring non-invasive ways to check for diabetic eye disease. Traditional tests often require dye injections, which can be uncomfortable. New imaging methods like Optical Coherence Tomography (OCT) and fundus photography are becoming more common. These tests are quick, painless, and offer high-quality images of the retina. They help detect changes in the eye before symptoms appear. Because they are easier to perform, more clinics are using them regularly. This shift improves patient comfort and encourages routine screenings. As a result, early diagnosis rates are going up worldwide.
Combination Therapies Gaining Popularity
Doctors are moving away from using just one treatment for diabetic retinopathy. Many now prefer combining anti-VEGF injections with laser therapy or corticosteroids. This mix can offer better results, especially in advanced cases. Combination therapy helps control swelling and reduces the chance of vision loss. It also allows treatment to be tailored based on how the disease is progressing. This approach is being tested in more clinical settings. As research continues, more doctors are adopting this method. Patients benefit from improved outcomes and longer-lasting results. The trend is expected to become a standard treatment in the near future.
Increasing Use of Teleophthalmology
Teleophthalmology is making diabetic eye care more accessible. With digital tools and internet platforms, doctors can now examine patients remotely. Retinal images are sent online, and eye specialists review them from afar. This is very helpful for people in rural or hard-to-reach areas. It cuts down on travel time and wait times for appointments. Healthcare systems are using teleophthalmology to screen more patients in less time. It also supports faster diagnosis and treatment. As the technology improves, more clinics and hospitals are adding it to their services. The trend is helping bridge the gap in eye care access.
Growing Emphasis on Early Diagnosis and Screening Programs
Governments and health organizations are urging diabetic patients to get regular eye exams. Early screening helps find diabetic retinopathy before it causes serious vision problems. National screening programs are being launched in many countries. These programs make eye checks part of routine diabetes care. Public awareness campaigns are also spreading the message. By catching the disease early, treatments can start sooner and reduce the risk of blindness. Clinics are using reminders and follow-up systems to make sure patients come back for exams. This focus on early detection is leading to better long-term eye health outcomes.
Personalized Treatment Plans with Genetic Insights
Scientists are studying how genetics affect the risk of diabetic retinopathy. Some people may be more likely to develop the disease based on their DNA. This research could lead to personalized treatment plans in the future. Doctors may one day use genetic tests to choose the best treatment for each patient. This would improve how well therapies work and reduce side effects. Though still in the early stages, the idea is gaining attention. Personalized care could become a key trend in diabetic eye treatment. It promises a more targeted and effective way to manage the disease.
Use Cases
Hospitals and Eye Clinics
Hospitals and eye clinics are key players in managing diabetic retinopathy. They use advanced imaging tools to screen patients with diabetes for early signs of eye damage. Common tools include fundus cameras and OCT scanners. If retinopathy is found, treatments like anti-VEGF injections or laser therapy are provided. These are usually performed in specialized ophthalmology departments. Hospitals also offer follow-up care and long-term monitoring. Their role is crucial in preventing vision loss in patients with diabetes. With skilled professionals and high-end tools, hospitals are often the first choice for both diagnosis and treatment of diabetic retinopathy.
Primary Care Centers
Primary care centers are becoming more involved in early detection of diabetic retinopathy. General physicians now conduct basic eye checks during routine diabetes visits. If any signs of retinal damage are noticed, patients are referred to eye specialists. This approach helps in catching the disease early. These centers also educate diabetic patients on the importance of regular eye exams. Their involvement reduces the load on hospitals and helps improve early diagnosis rates. By working closely with ophthalmologists, primary care centers create a smooth referral system for effective diabetic retinopathy management.
Rural and Remote Healthcare Settings
In rural and remote areas, access to eye care is limited. To bridge this gap, telemedicine is being widely used. Retinal images are captured locally and sent to specialists in urban hospitals. These experts review the images and provide a diagnosis remotely. This method speeds up early detection of diabetic retinopathy. It also reduces the need for patients to travel long distances for screening. Telemedicine helps bring expert eye care to underserved communities. As technology improves, this model is becoming more common and effective in rural healthcare settings.
Pharmacies and Optical Retail Chains
Large pharmacy chains and optical stores are now offering basic diabetic eye screenings. These services are available without a doctor’s appointment. They use non-invasive imaging tools to check for early signs of retinopathy. If any issues are found, customers are advised to visit an eye specialist. This setup is convenient for people who may not visit hospitals regularly. It also raises awareness about diabetic eye health. By offering quick and easy screenings, pharmacies and optical shops help increase early detection and reduce the risk of complications.
Mobile Eye Screening Units
Mobile eye screening units are helping reach people in underserved areas. These are vans equipped with diagnostic tools like fundus cameras. They visit rural villages, community centers, and schools. Trained technicians capture retinal images and send them to specialists for review. This method allows large numbers of diabetic individuals to be screened quickly. It is especially useful for those who rarely visit eye clinics. Mobile units improve access and help in early detection of diabetic retinopathy. They play a vital role in national eye care and public health programs.
Health Insurance and Wellness Programs
Health insurance companies are adding diabetic eye screening to their wellness packages. This encourages policyholders to go for preventive checkups. Early detection helps reduce long-term treatment costs and avoid vision-related claims. Some insurers even offer discounts or incentives for completing regular eye exams. These programs promote awareness and better diabetes management. They also help in reducing complications linked to diabetic retinopathy. Wellness initiatives supported by insurers are making eye care more accessible and affordable. As a result, more people are getting screened on time.
Academic and Research Institutes
Research institutions play a major role in understanding diabetic retinopathy. They study how the condition develops and test new treatment methods. Many institutes are exploring how artificial intelligence (AI) can improve early diagnosis. AI tools are being trained to detect even tiny changes in retinal images. These studies are helping create faster, more accurate screening methods. Research centers also publish findings that help shape treatment guidelines. Their work supports innovation and leads to better care strategies for diabetic patients. Academic contributions are essential in driving progress in this field.
Conclusion
In conclusion, the diabetic retinopathy market is growing steadily due to rising diabetes cases, better screening tools, and improved treatment options. New technologies like AI-based imaging and non-invasive diagnostics are helping doctors detect the disease early. Hospitals, clinics, and even pharmacies are expanding access to care, making it easier for patients to get regular eye exams. Rural areas are also benefiting from mobile units and telemedicine. Pharmaceutical companies are focusing on innovative drugs, while insurance programs are promoting early detection. With ongoing research and better awareness, the market is moving toward more effective and accessible diabetic eye care for people around the world.
View More
Diabetes Devices Market, Diabetes Treatment Devices Market, Diabetic Footwear Market, Diabetes Wearables Market, Diabetes Drugs Market, Antidiabetics Market, Diabetic Foot Ulcer Treatment Market, Diabetic Retinopathy Market, Digital Diabetes Management Market, Diabetes Management Apps Market, Retinoscopes Market
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
